The occurrence of blood clots and thrombocytopenia after vaccination with AstraZeneca and Johnson & Johnson’s COVID-19 vaccine has been recorded in reports from drug management agencies and vaccine safety monitoring organizations in many countries. .
The World Health Organization has requested vigilance, monitoring, early detection and timely treatment of rare events in people after COVID-19 vaccination with suspected thrombocytopenia, immune clots, and blood clots. scattered in the veins, cerebral venous blood clots. Clinical manifestations usually occur 4 to 42 days after COVID-19 vaccination.
The rate of blood clotting after AstraZeneca vaccination in young people is higher than in older people, especially in the 20-29 age group.
After vaccination with the AstraZeneca vaccine, the rate of blood clots seems to be less likely to occur in people over 60 years old, only about 0.2/1 million first doses.
Blood clotting complications after the AstraZeneca vaccine depend on genetic factors, underlying disease, lifestyle, and medications being used.
Based on the recommendations of medical organizations around the world on the possibility of complications of coagulation disorders after COVID-19 vaccination, with the proposal of the expert council, on April 22, 2021, the Ministry of Health has issued Guidelines for the diagnosis and treatment of thrombocytopenia syndrome and blood clots after COVID-19 vaccination (attached to Decision No. 1966 dated April 22, 2021).
Also according to the Department of Health of Ho Chi Minh City, the appearance of blood clots is a rare adverse event after COVID-19 vaccination, most occurring within 28 days and a few cases occurring after 42 days. (according to the Australian Ministry of Health).
This condition is completely treatable. Therefore, worrying about blood clotting disorders due to having been vaccinated against COVID-19 is unfounded.
Vaccination against COVID-19 in particular and vaccination against diseases in general are still effective measures to protect individuals and communities against dangerous infectious diseases.
Complying with regulations on vaccination safety and closely monitoring adverse events after vaccination plays an important role in preventing, detecting and treating adverse events after vaccination.
